Caladrius Biosciences (CLBS) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research downgraded shares of Caladrius Biosciences (NASDAQ:CLBS) from a hold rating to a sell rating in a research report released on Wednesday morning.

According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

Separately, HC Wainwright reiterated a buy rating and issued a $7.00 price objective on shares of Caladrius Biosciences in a report on Friday, November 10th.

Caladrius Biosciences (CLBS) traded down $0.08 during midday trading on Wednesday, reaching $3.92. The company’s stock had a trading volume of 37,431 shares, compared to its average volume of 64,116. Caladrius Biosciences has a 1-year low of $2.63 and a 1-year high of $7.79. The stock has a market cap of $37.32, a PE ratio of -1.89 and a beta of 1.59.

Caladrius Biosciences (NASDAQ:CLBS) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.41. equities analysts expect that Caladrius Biosciences will post -2.33 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc. grew its holdings in Caladrius Biosciences Inc (NASDAQ:CLBS) by 2.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 155,380 shares of the biotechnology company’s stock after buying an additional 4,163 shares during the quarter. Vanguard Group Inc.’s holdings in Caladrius Biosciences were worth $723,000 at the end of the most recent quarter. 6.41% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This article was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2018/01/11/caladrius-biosciences-clbs-downgraded-by-zacks-investment-research-to-sell.html.

About Caladrius Biosciences

Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply